NASDAQ
Valneva SE - American Depositary Shares (VALN)
♥ 397 Thanks from members
Valneva SE faces significant earnings headwinds, wider losses, and heavy impairment charges on its chikungunya vaccine, yet maintains a solid cash position and reaffirms full-year product sales guidance as the Lyme disease vaccine program advances toward upcoming regulatory decisions.